Long-term follow-up of autologous peripheral blood stem cell transplantation in the treatment of a patient with acute panmyelosis with myelofibrosis

Haematologica. 2006 Dec;91(12 Suppl):ECR53.

Authors

M C Ngirabacu¹, C Ravoet, J L Dargent, N Meuleman, I Ahmad, L Ysebrant, J Bennani, M André, D Bron

Affiliation

¹ Dept d'Hématologie de l'Institut J Bordet (Université libre de Bruxelles), Brussels, Belgium.

PMID: 17194659

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Acute Disease
Anemia, Refractory / drug therapy
Anemia, Refractory / etiology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Combined Modality Therapy
Cytarabine / administration & dosage
Erythropoietin / therapeutic use
Etoposide / administration & dosage
Follow-Up Studies
Granulocyte Colony-Stimulating Factor / therapeutic use
Humans
Leukemia, Myeloid / drug therapy
Leukemia, Myeloid / pathology
Leukemia, Myeloid / surgery*
Male
Methotrexate / administration & dosage
Middle Aged
Mitoxantrone / administration & dosage
Peripheral Blood Stem Cell Transplantation*
Postoperative Complications / drug therapy
Postoperative Complications / etiology
Primary Myelofibrosis / drug therapy
Primary Myelofibrosis / pathology
Primary Myelofibrosis / surgery*
Recombinant Proteins
Transplantation Conditioning / adverse effects
Transplantation, Autologous
Whole-Body Irradiation / adverse effects

Substances

Recombinant Proteins
Cytarabine
Erythropoietin
Granulocyte Colony-Stimulating Factor
Etoposide
Mitoxantrone
Methotrexate